2021
DOI: 10.3390/ph14050435
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Energy Expenditure—Drugs for Obesity Treatment

Abstract: Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing ene… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
15
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(18 citation statements)
references
References 108 publications
0
15
0
Order By: Relevance
“…Brown adipose tissue (BAT), which contains thermogenic brown and beige adipocytes [ 12 ], is capable of energy dissipation through the production of heat [ 13 ], mainly mediated by Uncoupling protein (UCP) 1-dependent proton leak, which uncouples oxidative phosphorylation from ATP generation in the mitochondria [ 14 ]. BAT plays a key role in maintaining the constant core body temperature through nonshivering thermogenesis [ 15 ] and might open up promising therapeutic opportunities to combat obesity [ 16 ]. BAT can be found in six anatomical regions (cervical, supraclavicular, axillary, mediastinal, paraspinal, and abdominal) in adult humans, which amount to 4.3% of total fat and 1.5% of total body mass [ 17 ].…”
Section: Introductionmentioning
confidence: 99%
“…Brown adipose tissue (BAT), which contains thermogenic brown and beige adipocytes [ 12 ], is capable of energy dissipation through the production of heat [ 13 ], mainly mediated by Uncoupling protein (UCP) 1-dependent proton leak, which uncouples oxidative phosphorylation from ATP generation in the mitochondria [ 14 ]. BAT plays a key role in maintaining the constant core body temperature through nonshivering thermogenesis [ 15 ] and might open up promising therapeutic opportunities to combat obesity [ 16 ]. BAT can be found in six anatomical regions (cervical, supraclavicular, axillary, mediastinal, paraspinal, and abdominal) in adult humans, which amount to 4.3% of total fat and 1.5% of total body mass [ 17 ].…”
Section: Introductionmentioning
confidence: 99%
“…49,107 PL-8905 is in clinical trials after exhibiting minimal side effects, such as changes in blood pressure, in preclinical studies. 49,108 Setmelanotide showed considerable promise with no observed side effects in phase III clinical trials 36 and has now been approved by the FDA. 108 Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), also causes weight loss by reducing appetite.…”
Section: Nonpeptide Ligandsmentioning
confidence: 99%
“…Brown adipose tissue (BAT), which contains thermogenic brown and beige adipocytes, is capable for energy dissipation through the production of heat, mainly mediated by Uncoupling protein (UCP) 1-dependent proton leak that uncouples oxidative phosphorylation from ATP generation in the mitochondria [12][13][14].BAT plays a key role in maintaining the constant core body temperature through non-shivering thermogenesis and might open up promising therapeutic opportunities to combat obesity [15,16]. BAT can be found in six anatomical regions (cervical, supraclavicular, axillary, mediastinal, paraspinal, and abdominal) in adult humans, which amounted to 4.3% of total fat and 1.5% of total body mass [17].…”
Section: Introductionmentioning
confidence: 99%